Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/849636/000149315218000222/form8-k.htm
May 2022
April 2022
March 2022
March 2022
March 2022
February 2022
January 2022
December 2021
December 2021
December 2021
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/849636/000149315218000222/form8-k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Respirerx Pharmaceuticals Inc..
Respirerx Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Ticker: RSPIEvents:
CIK: 849636
Form Type: 8-K Corporate News
Accession Number: 0001493152-18-000222
Submitted to the SEC: Fri Jan 05 2018 4:15:33 PM EST
Accepted by the SEC: Fri Jan 05 2018
Period: Friday, December 29, 2017
Industry: Pharmaceutical Preparations